Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies

Urology

Volumn 48, Issue 1, 1996, Pages 47-57

  Bostwick, David G ^a   Wheeler, Thomas M ^b   Blute, Michael ^b   Barrett, David M ^b   MacLennan, Gregory T ^b   Sebo, Thomas J ^b   Scardino, Peter T ^b   Humphrey, Peter A ^b   Hudson, M'liss A ^b   Fradet, Yves ^b   Miller, Gary J ^b   Crawford, E David ^b   Blumenstein, Brent A ^b   Mahran, Howard E ^b   Miles, Brian J ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; TUMOR VASCULARIZATION;

EID: 0030200923     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00149-5     Document Type: Article

References (47)

1. Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, Billebaud T, Delmas V, Meulemans A, Toublanc M, Boccon-Gibod L. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology. 44:1994;371-376.
2. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet. 1:1986;60-63.
3. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Capsular penetration in prostate cancer: significance for natural history and treatment. Am J Surg Pathol. 14:1990;240-247.
4. Hering F, Rist M, Roth J, Mihatsch M, Rutishauser G. Does microinvasion of the capsule and/or micrometastases in regional lymph nodes influence disease-free survival after radical prostatectomy? Br J Urol. 66:1990;177-181.
5. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol. 141:1989;1076-1083.
6. Kleer E, Larson-Keller JJ, Zincke H, Oesterling JE. Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade. Urology. 41:1993;207-212.
7. Mukamel E, deKernion JB, Dorey F, Hannah J. Significance of histological prognostic indicators in patients with carcinoma of the prostate. Br J Urol. 65:1990;46-51.
8. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. The use of prostate-specific antigen, clinical stage, and Gleason score to predict pathologic stage in men with localized prostate cancer. J Urol. 150:1993;110-116.
9. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression following radical retropubic prostatectomy. Cancer. 71:1993;3582-3587.
10. Bostwick DG, Myers RP, Oesterling JE. Staging of prostate cancer. Semin Surg Oncol. 10:1994;60-72.
11. Ackerman DA, Barry JM, Wicklund RA, Olson N, Lowe BA. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol. 150:1993;1845-1851.
12. Bostwick DG, Qian J, Bergstrahl E, Dundore P, Dugan J, Myers RP, Oesterling JE. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol. 155:1996;1361-1367.
13. Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol. 153:1995;1543-1548.
14. Wakui S, Furusato M, et al. Tumor angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J Pathol. 168:1992;257-262.
15. Brawer MK, Bigler SA, Deering RE. Quantitative morphometric analysis of the microcirculation in prostate carcinoma. J Cell Biochem Suppl. 1992;62-64.
16. Weidner N, Carroll P, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 143:1993;401-409.
17. Fregene T, Khanuja P, Noto AC, Gehani SK, Van Egmont EM, Luz DA, Pienta KJ. Tumor-associated angiogenesis in prostate cancer. Anticancer Res. 13:1993;2377-2382.
18. Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol. 24:1993;220-226.
19. Montironi R, Magi Galluzzi CM, Damanti L, Taborro R, Scarpelli M, Pisani E. Prostatic intra-epithelial neoplasia. Qualitative and quantitative analyses of the blood capillary architecture on thin tissue sections. Pathol Res Pract. 189:1993;542-548.
20. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer. 73:1994;678-687.
21. Hall MC, Troncoso P, Pollack A, Zhau HY, Zagars GK, Chung LW, von Eschenbach AC. Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology. 44:1994;869-875.
22. Vesalainen S, Lipponen P, Talja M, Alhava E, Syrjanen K. Tumor vascularity and basement membrane struture as prognostic factors in T1-2MO prostatic adenocarcinoma. Anticancer Res. 14:1994;709-714.
23. Siegal JA, Yu E, Brawer MK. Topography of neovascularity in human prostate carcinoma. Cancer. 75:1995;2545-2551.
24. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol. 10:1993;302-313.
25. Weidner N, Semple J, Semple JP, Welch WA, Folkman J. Tumor angiogenesis and metastasis. Correlation in invasive breast carcinoma. N Engl J Med. 324:1991;1-8.
26. Harris AL, Horak E. Growth factors and angiogenesis in breast cancer. Recent results. Cancer Res. 127:1993;35-41.
27. Jaeger TM, Weidner N, Chew K, Moore DH, Kerschmann RL, Waldman FM, Carroll PR. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol. 154:1995;69-71.
28. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularization to metastasis of non small cell lung cancer. Lancet. 340:1992;145-146.
29. Tomisaki S-I, Ohno S, Ichiyoshi Y, Kuwano H, Maehara Y, Sugimachi K. Microvessel quantification and its possible relation with liver metastasis in colorectal cancer. Cancer. 77:1996;1722-1728.
30. Myrtle JF, Klimley PG, Ivor LP, Bruni JF. Clinical utility of prostate specific antigen (PSA) in the management of prostate cancer. Advances in Cancer Diagnosis. 1986;Hybritech, Inc. La Jolla, Calif.
31. Sakr W, Wheeler T, Blute M, Bodo M, Calle-Rodrigue R, Henson D, Mostofi FK, Seiffert J, Wojno K, Zincke H. Staging and reporting of prostate cancer. Sampling of the radical prostatectomy specimen. Cancer. 1996;. (in press).
32. Ohori M, Scardino PT, Lapin SL, Seale-Hawkins C, Link J, Wheeler TM. The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am J Surg Pathol. 17:1993;1252-1259.
33. Epstein JI, Carmichael M, Walsh PC. Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade, and margins of resection to prognosis. J Urol. 149:1993;1040-1045.
34. Shroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate Suppl. 4:1992;129-138.
35. Folkman J, Klagsburn M. Angiogenic factors. Science. 235:1987;442-447.
36. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 3:1992;65-71.
37. Folkman J, Shing Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol. 313:1992;355-364.
38. Nagy JA, Brown LF, Senger DR, Lanir N, Van de Water L, Dvorak AM, Dvorak HF. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochem Biophys Acta. 948:1989;305-326.
39. Matuo Y, McKeehan WL, Yan GC, Nikolaropoulos S, Adams PS, Fukabori Y, Yamanaka H, Gaudreau J. Potential role of HBGH (FGF) and TGF-beta on prostate growth. Adv Exp Med Biol. 324:1992;107-114.
40. Brown LF, Yeo KT, Berse B, Morgentaler A, Dvorak HF, Rosen S. Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. J Urol. 154:1995;576-579.
41. Sinha AA, Gleason DF, Staley NA, Wilson MJ, Sameni M, Sloane BF. Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis. Anat Rec. 241:1995;353-362.
42. Lokeshwar VB, Lekeshwar BL, Pham HT, Block NL. Association of elevated levels of hyalurondiase, a matrix-degrading enzyme, with prostate cancer progression. Cancer Res. 56:1996;651-657.
43. Seksela O, Moscatelli D, Sommer A, Rikfin DB. Endothelial cell derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol. 107:1988;743-751.
44. Vartanian RK, Weidner N. Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's core, microvessel density, and epithelial cell proliferation. Lab Invest. 73:1995;844-850.
45. Salamao DR, Graham SD, Bostwick DG. Microvascular invasion in prostate cancer correlates with pathologic stage. Arch Pathol Lab Med. 119:1995;1050-1054.
46. Bahnson RR, Dresner SM, Gooding W, Becich MJ. Incidence and prognostic significance of lymphatic and vascular invasion in radical prostatectomy specimens. Prostate. 15:1989;149-155.
47. Katz AE, Olsson CA, Raffo AJ, Cama C, Perlman H, Seaman E, O'Toole KM, McMahon D, Benson MC, Buttyan R. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology. 43:1994;765-775.